These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 32241015)

  • 1. Three-Dimensional Primary Cell Culture: A Novel Preclinical Model for Pancreatic Neuroendocrine Tumors.
    April-Monn SL; Wiedmer T; Skowronska M; Maire R; Schiavo Lena M; Trippel M; Di Domenico A; Muffatti F; Andreasi V; Capurso G; Doglioni C; Kim-Fuchs C; Gloor B; Zatelli MC; Partelli S; Falconi M; Perren A; Marinoni I
    Neuroendocrinology; 2021; 111(3):273-287. PubMed ID: 32241015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting Focal Adhesion Kinase and Resistance to mTOR Inhibition in Pancreatic Neuroendocrine Tumors.
    François RA; Maeng K; Nawab A; Kaye FJ; Hochwald SN; Zajac-Kaye M
    J Natl Cancer Inst; 2015 Aug; 107(8):. PubMed ID: 25971297
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current understanding of the molecular biology of pancreatic neuroendocrine tumors.
    Zhang J; Francois R; Iyer R; Seshadri M; Zajac-Kaye M; Hochwald SN
    J Natl Cancer Inst; 2013 Jul; 105(14):1005-17. PubMed ID: 23840053
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autophagy Inhibition Improves Sunitinib Efficacy in Pancreatic Neuroendocrine Tumors via a Lysosome-dependent Mechanism.
    Wiedmer T; Blank A; Pantasis S; Normand L; Bill R; Krebs P; Tschan MP; Marinoni I; Perren A
    Mol Cancer Ther; 2017 Nov; 16(11):2502-2515. PubMed ID: 28729403
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interaction between somatostatin analogues and targeted therapies in neuroendocrine tumor cells.
    Krug S; Mordhorst JP; Moser F; Theuerkorn K; Ruffert C; Egidi M; Rinke A; Gress TM; Michl P
    PLoS One; 2019; 14(6):e0218953. PubMed ID: 31237925
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rb and p53 Execute Distinct Roles in the Development of Pancreatic Neuroendocrine Tumors.
    Yamauchi Y; Kodama Y; Shiokawa M; Kakiuchi N; Marui S; Kuwada T; Sogabe Y; Tomono T; Mima A; Morita T; Matsumori T; Ueda T; Tsuda M; Nishikawa Y; Kuriyama K; Sakuma Y; Ota Y; Maruno T; Uza N; Masuda A; Tatsuoka H; Yabe D; Minamiguchi S; Masui T; Inagaki N; Uemoto S; Chiba T; Seno H
    Cancer Res; 2020 Sep; 80(17):3620-3630. PubMed ID: 32591410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cross-talk among MEN1, p53 and Notch regulates the proliferation of pancreatic neuroendocrine tumor cells by modulating INSM1 expression and subcellular localization.
    Capodanno Y; Chen Y; Schrader J; Tomosugi M; Sumi S; Yokoyama A; Hiraoka N; Ohki R
    Neoplasia; 2021 Sep; 23(9):979-992. PubMed ID: 34352404
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MEN1 Degradation Induced by Neddylation and the CUL4B-DCAF7 Axis Promotes Pancreatic Neuroendocrine Tumor Progression.
    Xu J; Ye Z; Zhuo Q; Gao H; Qin Y; Lou X; Zhang W; Wang F; Wang Y; Jing D; Fan G; Zhang Y; Chen X; Chen J; Xu X; Yu X; Ji S
    Cancer Res; 2023 Jul; 83(13):2226-2247. PubMed ID: 36939378
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacodynamics, clinical findings and approval status of current and emerging tyrosine-kinase inhibitors for pancreatic neuroendocrine tumors.
    Fazio N; Cella CA; Del Re M; Laffi A; Rubino M; Zagami P; Spada F
    Expert Opin Drug Metab Toxicol; 2019 Dec; 15(12):993-1004. PubMed ID: 31794273
    [No Abstract]   [Full Text] [Related]  

  • 10. Sunitinib-Loaded Chondroitin Sulfate Hydrogels as a Novel Drug-Delivery Mechanism for the Treatment of Pancreatic Neuroendocrine Tumors.
    Keutgen XM; Ornell KJ; Vogle A; Lakiza O; Williams J; Miller P; Mistretta KS; Setia N; Weichselbaum RR; Coburn JM
    Ann Surg Oncol; 2021 Dec; 28(13):8532-8543. PubMed ID: 34091777
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A review of functional pancreatic neuroendocrine tumors: Exploring the molecular pathogenesis, diagnosis and treatment.
    Alshareefy Y; Cummins S; Mazzoleni A; Sharma V; Guggilapu S; Leong AWY; Wireko AA
    Medicine (Baltimore); 2023 Nov; 102(46):e36094. PubMed ID: 37986400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PHLDA3 is a novel tumor suppressor of pancreatic neuroendocrine tumors.
    Ohki R; Saito K; Chen Y; Kawase T; Hiraoka N; Saigawa R; Minegishi M; Aita Y; Yanai G; Shimizu H; Yachida S; Sakata N; Doi R; Kosuge T; Shimada K; Tycko B; Tsukada T; Kanai Y; Sumi S; Namiki H; Taya Y; Shibata T; Nakagama H
    Proc Natl Acad Sci U S A; 2014 Jun; 111(23):E2404-13. PubMed ID: 24912192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Cross-Species Analysis in Pancreatic Neuroendocrine Tumors Reveals Molecular Subtypes with Distinctive Clinical, Metastatic, Developmental, and Metabolic Characteristics.
    Sadanandam A; Wullschleger S; Lyssiotis CA; Grötzinger C; Barbi S; Bersani S; Körner J; Wafy I; Mafficini A; Lawlor RT; Simbolo M; Asara JM; Bläker H; Cantley LC; Wiedenmann B; Scarpa A; Hanahan D
    Cancer Discov; 2015 Dec; 5(12):1296-313. PubMed ID: 26446169
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Placenta-Specific 8 Is Overexpressed and Regulates Cell Proliferation in Low-Grade Human Pancreatic Neuroendocrine Tumors.
    Tatura M; Schmidt H; Haijat M; Stark M; Rinke A; Diels R; Lawlor RT; Scarpa A; Schrader J; Hackert T; Schimmack S; Gress TM; Buchholz M
    Neuroendocrinology; 2020; 110(1-2):23-34. PubMed ID: 31018208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined Targeting of Pathogenetic Mechanisms in Pancreatic Neuroendocrine Tumors Elicits Synergistic Antitumor Effects.
    Gulde S; Foscarini A; April-Monn SL; Genio E; Marangelo A; Satam S; Helbling D; Falconi M; Toledo RA; Schrader J; Perren A; Marinoni I; Pellegata NS
    Cancers (Basel); 2022 Nov; 14(22):. PubMed ID: 36428573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RSUME is implicated in tumorigenesis and metastasis of pancreatic neuroendocrine tumors.
    Wu Y; Tedesco L; Lucia K; Schlitter AM; Garcia JM; Esposito I; Auernhammer CJ; Theodoropoulou M; Arzt E; Renner U; Stalla GK
    Oncotarget; 2016 Sep; 7(36):57878-57893. PubMed ID: 27506944
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patterns and predictors of pancreatic neuroendocrine tumor prognosis: Are no two leaves alike?
    Gao H; Wang W; Yu X; Liu L
    Crit Rev Oncol Hematol; 2021 Nov; 167():103493. PubMed ID: 34653597
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Temozolomide Alone or Combined with Capecitabine for the Treatment of Advanced Pancreatic Neuroendocrine Tumor.
    de Mestier L; Walter T; Evrard C; de Boissieu P; Hentic O; Cros J; Tougeron D; Lombard-Bohas C; Rebours V; Hammel P; Ruszniewski P
    Neuroendocrinology; 2020; 110(1-2):83-91. PubMed ID: 31071715
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A growth model of neuroendocrine tumor surrogates and the efficacy of a novel somatostatin-receptor-guided antibody-drug conjugate: Perspectives on clinical response?
    Herring B; Whitt J; Aweda T; Ou J; Guenter R; Lapi S; Berry J; Chen H; Liu X; Rose JB; Jaskula-Sztul R
    Surgery; 2020 Jan; 167(1):197-203. PubMed ID: 31543319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Eighth Edition of the American Joint Committee on Cancer Distant Metastases Stage Classification for Metastatic Pancreatic Neuroendocrine Tumors Might Be Feasible for Metastatic Pancreatic Ductal Adenocarcinomas.
    Wen J; Chen J; Liu D; Xu X; Fan M; Zhang Z
    Neuroendocrinology; 2020; 110(5):364-376. PubMed ID: 31357196
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.